Rita Mateus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rita Mateus has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
J. Hadgraft
2 shared publicationsJonathan Hadgraft
Department of Pharmaceutics, UCL School of Pharmacy, London, UK
2 shared publications- Lucilia Pereira
BET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal
2 shared publications - Mafalda Videira
Departamento de Farmácia Galénica e de Tecnologia Farmacêutica, Faculdade de Farmácia da Universidade de Lisboa, iMed.ULisboa-Research Institute for Medicines and Pharmaceutical Sciences, Lisbon, Portugal
2 shared publications - Majella E. Lane
Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK
2 shared publications Alexandra Brito
1 shared publication
Latest Publications
- 15 July 2015
- Published by Wiley
- p. 41-55
Application of Spectroscopic Techniques to Interrogate Skin
- 6 February 2015
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 17 (2) , 1-13
Host-directed strategies using lipid nanoparticles to reduce mycobacteria survival
- 6 February 2015
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 17 (2) , 1-13
Host-directed strategies using lipid nanoparticles to reduce mycobacteria survival
- 9 January 2015
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 14 (9) , 832-849
Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
The expression of CD44 tags cells with stemness-associated properties (cancer initiating cells or cancer stem cells - CSC). This membrane glycoprotein with a cytoplasmic domain indirectly associated with the cellular cytoskeleton, has a crucial role in tumorigenesis. The CD44 receptor enables the cell to respond to changes in tumor microenvironment, promoting several signaling events related to tumor initiation, progression and fixation in distant host tissues. Although the contribution of this transmembrane protein in gene regulation remains unclear, its overexpression in adenocarcinomas, mostly supported by microRNA (miR)-mediated upregulation of target mRNA, is widely accepted. Herein, we gather the evidence that CD44 is one of the most predominant markers of malignant cells and may be found in diverse phenotypes associated with tumor progression. Additionally, CD44 tumor receptors were found to have different roles at a transcriptional level. Thus, innovative therapeutic strategies should rely heavily on its metastasis-promoting ability. Furthermore, the concept of selectively targeting cell sub-populations may be used to develop specific therapeutic and/or diagnostic systems. An approach based on targeting CD44+ cells might provide a strategy to design guided-therapeutic systems against multiple malignant cells including putative CSC.
- 9 January 2015
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 14 (9) , 832-849
Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
The expression of CD44 tags cells with stemness-associated properties (cancer initiating cells or cancer stem cells - CSC). This membrane glycoprotein with a cytoplasmic domain indirectly associated with the cellular cytoskeleton, has a crucial role in tumorigenesis. The CD44 receptor enables the cell to respond to changes in tumor microenvironment, promoting several signaling events related to tumor initiation, progression and fixation in distant host tissues. Although the contribution of this transmembrane protein in gene regulation remains unclear, its overexpression in adenocarcinomas, mostly supported by microRNA (miR)-mediated upregulation of target mRNA, is widely accepted. Herein, we gather the evidence that CD44 is one of the most predominant markers of malignant cells and may be found in diverse phenotypes associated with tumor progression. Additionally, CD44 tumor receptors were found to have different roles at a transcriptional level. Thus, innovative therapeutic strategies should rely heavily on its metastasis-promoting ability. Furthermore, the concept of selectively targeting cell sub-populations may be used to develop specific therapeutic and/or diagnostic systems. An approach based on targeting CD44+ cells might provide a strategy to design guided-therapeutic systems against multiple malignant cells including putative CSC.
- 1 November 2014
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 475 (1-2) , 471-474
Percutaneous absorption of salicylic acid – in vitro and in vivo studies
- 1 November 2014
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 475 (1-2) , 471-474
Percutaneous absorption of salicylic acid – in vitro and in vivo studies
- 1 February 2013
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 444 (1-2) , 106-108
A new paradigm in dermatopharmacokinetics – Confocal Raman spectroscopy
- 1 February 2013
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 444 (1-2) , 106-108
A new paradigm in dermatopharmacokinetics – Confocal Raman spectroscopy
- 18 January 2011
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 406 (1-2) , 111-113
Opto-Thermal Transient Emission Radiometry (OTTER) to image diffusion in nails in vivo
- 18 January 2011
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 406 (1-2) , 111-113
Opto-Thermal Transient Emission Radiometry (OTTER) to image diffusion in nails in vivo